Carla Santomasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Carla Santomasi has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Giovanna Elisiana Carpagnano
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, 70121 Bari, Italy
10 shared publications - Andrea Portacci
Institute of Respiratory Disease, Department of Translational Biomedicine and neuroscience, University “Aldo Moro”, Bari, Italy, Bari, Italy
7 shared publications - Silvano Dragonieri
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, 70121 Bari, Italy
7 shared publications - Vitaliano Nicola Quaranta
Department of Respiratory Diseases, University of Bari, 70121 Bari, Italy
6 shared publications - Alfredo Vozza
Interdisciplinary Department of Medicine, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare 11, 70124 Bari, Italy
3 shared publications - Valentina Di Lecce
Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, 70124 Bari, Italy
3 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in Clocks & Sleep
- Vol. 8 (4) , 61
Can Sleep Hypoxic Measures Predict Long-Term Adherence to Positive Airway Pressure Treatments?
Obstructive sleep apnea (OSA) is a prevalent sleep-related breathing disorder characterized by recurrent upper airway collapse. Continuous positive airway pressure (CPAP) is the gold standard treatment but is burdened by low adherence rates. Nighttime hypoxia may alter sleep structure and OSA symptoms, potentially affecting PAP treatment adherence. This study aims to evaluate whether nocturnal hypoxia measures could predict long-term PAP adherence. We conducted a real-life, retrospective study including 207 OSA patients. Clinical data were collected on symptoms, comorbidities, home sleep apnea test (HSAT) metrics, prescribed therapy and objective adherence data via in-built device software. Nocturnal respiratory failure (NRF) was defined as a total sleep time with SpO2 < 90% (TST90) ≥ 30%. Among the cohort, 119 patients met the criteria for NRF. These patients exhibited higher BMI, more severe OSA and a higher prevalence of COPD compared to those without NRF. At follow-up, patients with NRF demonstrated significantly better treatment adherence and more frequently reported improvement in several daytime and nighttime symptoms. Time-to-event analysis and adjusted multivariable regressions showed a higher probability of good long-term PAP adherence in patients with TST90 ≥ 30%. These findings suggest that prolonged nocturnal hypoxemia may identify a subgroup of patients more likely to maintain long-term PAP treatment.
- 28 September 2026
- Published by MDPI AG in Clocks & Sleep
- Vol. 8 (4) , 61
Open AccessCan Sleep Hypoxic Measures Predict Long-Term Adherence to Positive Airway Pressure Treatments?
Obstructive sleep apnea (OSA) is a prevalent sleep-related breathing disorder characterized by recurrent upper airway collapse. Continuous positive airway pressure (CPAP) is the gold standard treatment but is burdened by low adherence rates. Nighttime hypoxia may alter sleep structure and OSA symptoms, potentially affecting PAP treatment adherence. This study aims to evaluate whether nocturnal hypoxia measures could predict long-term PAP adherence. We conducted a real-life, retrospective study including 207 OSA patients. Clinical data were collected on symptoms, comorbidities, home sleep apnea test (HSAT) metrics, prescribed therapy and objective adherence data via in-built device software. Nocturnal respiratory failure (NRF) was defined as a total sleep time with SpO2 < 90% (TST90) ≥ 30%. Among the cohort, 119 patients met the criteria for NRF. These patients exhibited higher BMI, more severe OSA and a higher prevalence of COPD compared to those without NRF. At follow-up, patients with NRF demonstrated significantly better treatment adherence and more frequently reported improvement in several daytime and nighttime symptoms. Time-to-event analysis and adjusted multivariable regressions showed a higher probability of good long-term PAP adherence in patients with TST90 ≥ 30%. These findings suggest that prolonged nocturnal hypoxemia may identify a subgroup of patients more likely to maintain long-term PAP treatment.
- Open Access
Exploratory Identification of Multidimensional COPD Clusters Using Unsupervised Analysis
Background and Objectives: COPD is a heterogeneous disease in which conventional clinical classifications may not fully capture the complexity of patient profiles. This exploratory study aimed to examine whether multidimensional COPD phenotypes could be identified using unsupervised cluster analysis integrating clinical, functional, radiological and laboratory features. Materials and Methods: We enrolled 161 patients with confirmed COPD evaluated between January 2020 and January 2024. Demographic, clinical, functional, radiological and laboratory findings were collected. Mixed-type data were analyzed using Gower distance and Partitioning Around Medoids (PAM) clustering. The optimal solution was selected by average silhouette width; stability was assessed by 1000 bootstrap resamples and sensitivity analyses. Results: The two-cluster solution had the highest silhouette width (0.184), although separation was modest. Cluster 1 (n = 78) was characterized by greater symptom and exacerbation burden, worse lung function, greater static hyperinflation, shorter 6-min walking distance and more frequent emphysema than cluster 2 (n = 83). Bootstrap resampling indicated internal stability, although concordance with the primary partition varied across sensitivity analyses. After correction for multiple post hoc comparisons, only LAMA/LABA/ICS use differed between clusters, whereas demographic characteristics, comorbidity burden and blood eosinophil levels were comparable. Conclusions: These exploratory findings suggest multidimensional assessment may complement conventional classifications, but external and longitudinal validation is needed before clinical implementation.
Open AccessExploratory Identification of Multidimensional COPD Clusters Using Unsupervised Analysis
Background and Objectives: COPD is a heterogeneous disease in which conventional clinical classifications may not fully capture the complexity of patient profiles. This exploratory study aimed to examine whether multidimensional COPD phenotypes could be identified using unsupervised cluster analysis integrating clinical, functional, radiological and laboratory features. Materials and Methods: We enrolled 161 patients with confirmed COPD evaluated between January 2020 and January 2024. Demographic, clinical, functional, radiological and laboratory findings were collected. Mixed-type data were analyzed using Gower distance and Partitioning Around Medoids (PAM) clustering. The optimal solution was selected by average silhouette width; stability was assessed by 1000 bootstrap resamples and sensitivity analyses. Results: The two-cluster solution had the highest silhouette width (0.184), although separation was modest. Cluster 1 (n = 78) was characterized by greater symptom and exacerbation burden, worse lung function, greater static hyperinflation, shorter 6-min walking distance and more frequent emphysema than cluster 2 (n = 83). Bootstrap resampling indicated internal stability, although concordance with the primary partition varied across sensitivity analyses. After correction for multiple post hoc comparisons, only LAMA/LABA/ICS use differed between clusters, whereas demographic characteristics, comorbidity burden and blood eosinophil levels were comparable. Conclusions: These exploratory findings suggest multidimensional assessment may complement conventional classifications, but external and longitudinal validation is needed before clinical implementation.
- Open Access
- 27 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 206
Distinct Hypoxemic Profiles of Obstructive Sleep Apnea in Southern Italy: The Living with OSA and CPAP Study
Background: Obstructive sleep apnea (OSA) is a heterogeneous disorder associated with substantial cardiometabolic and neurocognitive morbidity. Although the apnea–hypopnea index (AHI) remains the conventional measure of OSA severity, it only partially reflects the underlying pathophysiological complexity. Growing evidence indicates that nocturnal hypoxemia may be a more powerful marker of adverse outcomes than event frequency alone. Therefore, this study aimed to identify distinct OSA phenotypes based on oximetry-derived features and to assess whether these profiles offer additional clinical insight beyond traditional AHI-based classification. Methods: This multicenter retrospective study, part of the Living with OSA and CPAP: The Apulia Region Experience project, included 1386 adults diagnosed with OSA across 15 sleep centers in Southern Italy. Standardized clinical, anthropometric, and polysomnographic (PSG) data were collected. Hierarchical clustering analysis was performed based on PSG oximetry-derived variables. Resulting clusters were compared across demographic, clinical, hypoxemic, and therapeutic features. Results: Three reproducible clusters emerged. Cluster 1 (mild–non-obese) included younger, leaner patients with lower AHI (22.9 ± 10.5 events·h−1), minimal desaturation (T90 5.6 ± 7.6%), and limited comorbidities. Cluster 2 (severe–obese–hypoxemic) represented the most critical phenotype, characterized by marked obesity (BMI 39.2 ± 8.2 kg·m−2), severe OSA (AHI 74.9 ± 17.9 events·h−1), profound nocturnal hypoxemia (T90 51.5 ± 28.2%), and a high prevalence of metabolic disorders (76%), requiring higher CPAP pressures and frequent oxygen supplementation. Cluster 3 (older–comorbid) comprised older males (63.7 ± 11.8 years) with moderate-to-severe OSA (AHI 44.8 ± 15.2 events·h−1) and multiple cardiometabolic comorbidities. Conclusions: Oximetry-derived variables identify distinct and clinically meaningful OSA phenotypes that extend beyond traditional AHI-based classification. Recognizing hypoxemia-driven subtypes could improve risk stratification and enable more personalized management strategies in clinical practice.
- 27 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 206
Open AccessDistinct Hypoxemic Profiles of Obstructive Sleep Apnea in Southern Italy: The Living with OSA and CPAP Study
Background: Obstructive sleep apnea (OSA) is a heterogeneous disorder associated with substantial cardiometabolic and neurocognitive morbidity. Although the apnea–hypopnea index (AHI) remains the conventional measure of OSA severity, it only partially reflects the underlying pathophysiological complexity. Growing evidence indicates that nocturnal hypoxemia may be a more powerful marker of adverse outcomes than event frequency alone. Therefore, this study aimed to identify distinct OSA phenotypes based on oximetry-derived features and to assess whether these profiles offer additional clinical insight beyond traditional AHI-based classification. Methods: This multicenter retrospective study, part of the Living with OSA and CPAP: The Apulia Region Experience project, included 1386 adults diagnosed with OSA across 15 sleep centers in Southern Italy. Standardized clinical, anthropometric, and polysomnographic (PSG) data were collected. Hierarchical clustering analysis was performed based on PSG oximetry-derived variables. Resulting clusters were compared across demographic, clinical, hypoxemic, and therapeutic features. Results: Three reproducible clusters emerged. Cluster 1 (mild–non-obese) included younger, leaner patients with lower AHI (22.9 ± 10.5 events·h−1), minimal desaturation (T90 5.6 ± 7.6%), and limited comorbidities. Cluster 2 (severe–obese–hypoxemic) represented the most critical phenotype, characterized by marked obesity (BMI 39.2 ± 8.2 kg·m−2), severe OSA (AHI 74.9 ± 17.9 events·h−1), profound nocturnal hypoxemia (T90 51.5 ± 28.2%), and a high prevalence of metabolic disorders (76%), requiring higher CPAP pressures and frequent oxygen supplementation. Cluster 3 (older–comorbid) comprised older males (63.7 ± 11.8 years) with moderate-to-severe OSA (AHI 44.8 ± 15.2 events·h−1) and multiple cardiometabolic comorbidities. Conclusions: Oximetry-derived variables identify distinct and clinically meaningful OSA phenotypes that extend beyond traditional AHI-based classification. Recognizing hypoxemia-driven subtypes could improve risk stratification and enable more personalized management strategies in clinical practice.
- Open Access
- 11 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8771
Real-Life Characteristics of Patients with COPD and Discordant CAT-mMRC Questionnaires
Background/Objective: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends using the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) scale for symptom assessment. However, discordant results between these tools are common and may affect clinical phenotyping and treatment decisions. This study aims to identify clinical, functional, and radiological characteristics associated with discordant CAT and mMRC scores in COPD and assess the stability of this classification over time. Methods: We retrospectively analyzed 222 COPD patients classified into GOLD A, B, E, or a newly defined discordant group (GOLDD), characterized by CAT ≥ 10 with mMRC < 2 or CAT < 10 with mMRC ≥ 2. Clinical, functional, laboratory, and imaging data were collected. Logistic regression identified predictors of GOLD classification. GOLD group changes were assessed at follow-up. Results: At baseline, 12.8% of patients belonged to the GOLDD group. Compared to GOLD A and B, these patients had lower occupational exposure and higher rates of chest HRCT findings such as consolidations and centrilobular nodules. Regression models confirmed these features and identified FEV1 and FVC as independent predictors. GOLD classification showed notable variability during follow-up. Conclusions: Patients with discordant CAT-mMRC scores display distinct clinical and radiologic traits not captured by standard GOLD categories. These results underscore the limitations of relying solely on symptom scores and support a more comprehensive, trait-based approach to COPD assessment and management.
- 11 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8771
Open AccessReal-Life Characteristics of Patients with COPD and Discordant CAT-mMRC Questionnaires
Background/Objective: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends using the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) scale for symptom assessment. However, discordant results between these tools are common and may affect clinical phenotyping and treatment decisions. This study aims to identify clinical, functional, and radiological characteristics associated with discordant CAT and mMRC scores in COPD and assess the stability of this classification over time. Methods: We retrospectively analyzed 222 COPD patients classified into GOLD A, B, E, or a newly defined discordant group (GOLDD), characterized by CAT ≥ 10 with mMRC < 2 or CAT < 10 with mMRC ≥ 2. Clinical, functional, laboratory, and imaging data were collected. Logistic regression identified predictors of GOLD classification. GOLD group changes were assessed at follow-up. Results: At baseline, 12.8% of patients belonged to the GOLDD group. Compared to GOLD A and B, these patients had lower occupational exposure and higher rates of chest HRCT findings such as consolidations and centrilobular nodules. Regression models confirmed these features and identified FEV1 and FVC as independent predictors. GOLD classification showed notable variability during follow-up. Conclusions: Patients with discordant CAT-mMRC scores display distinct clinical and radiologic traits not captured by standard GOLD categories. These results underscore the limitations of relying solely on symptom scores and support a more comprehensive, trait-based approach to COPD assessment and management.
- Open Access
- 9 April 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (2) , 1-9
The impact of PAP therapy first impression on short-term treatment adherence
Purpose: Positive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) is often burdened by lower adherence rates. Patients’ perception and acceptance of PAP therapy play a crucial role in achieving acceptable adherence. Method: We conducted a prospective cohort study to assess patients’ initial impressions of PAP therapy using a six-item questionnaire. The questionnaire evaluated CPAP tolerance, interface comfort, titration pressure, likelihood of CPAP use, expected health benefits, and overall attitude toward PAP therapy. Patients underwent a baseline awake PAP therapy trial (T0) followed by titration with an automatic device (APAP). After one month of titration, a fixed CPAP value was set (T1). Follow-ups occurred at 1 (T2), 3 (T3), and 6 (T4) months after the start of treatment. Adherence to PAP therapy was considered sufficient if the mean device usage was ≥ 4 h/night at T4. Results: After six months, 77% of the enrolled patients achieved high PAP treatment adherence. Questionnaire scores generally improved from T0 to T4, particularly in CPAP tolerance, likelihood of treatment adherence, expected health benefits, and overall judgment of PAP therapy. Time-to-event analysis revealed that higher baseline scores in titration pressure comfort, likelihood of CPAP adherence, and overall judgment of PAP therapy were significantly associated with higher adherence likelihood. Conclusion: Patients’ first judgement on PAP therapy could significantly influence short-term adherence. Early identification and management of patients’ complaints and discomforts could improve adherence rates and PAP perception over time.
- 9 April 2025
- Published by Springer Nature in Sleep and Breathing
- Vol. 29 (2) , 1-9
Open AccessThe impact of PAP therapy first impression on short-term treatment adherence
Purpose: Positive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) is often burdened by lower adherence rates. Patients’ perception and acceptance of PAP therapy play a crucial role in achieving acceptable adherence. Method: We conducted a prospective cohort study to assess patients’ initial impressions of PAP therapy using a six-item questionnaire. The questionnaire evaluated CPAP tolerance, interface comfort, titration pressure, likelihood of CPAP use, expected health benefits, and overall attitude toward PAP therapy. Patients underwent a baseline awake PAP therapy trial (T0) followed by titration with an automatic device (APAP). After one month of titration, a fixed CPAP value was set (T1). Follow-ups occurred at 1 (T2), 3 (T3), and 6 (T4) months after the start of treatment. Adherence to PAP therapy was considered sufficient if the mean device usage was ≥ 4 h/night at T4. Results: After six months, 77% of the enrolled patients achieved high PAP treatment adherence. Questionnaire scores generally improved from T0 to T4, particularly in CPAP tolerance, likelihood of treatment adherence, expected health benefits, and overall judgment of PAP therapy. Time-to-event analysis revealed that higher baseline scores in titration pressure comfort, likelihood of CPAP adherence, and overall judgment of PAP therapy were significantly associated with higher adherence likelihood. Conclusion: Patients’ first judgement on PAP therapy could significantly influence short-term adherence. Early identification and management of patients’ complaints and discomforts could improve adherence rates and PAP perception over time.
- Open Access
Assessment of Five Questionnaires for Chronic Obstructive Pulmonary Disease in a Southern Italian Population: A Proof-of-Concept Study
Background and Objectives: Chronic obstructive pulmonary disease (COPD) is a growing burden to society, and remains underdiagnosed in Italy. This study aimed at evaluating five validated screening questionnaires to consider which one was the most accurate, and the optimal cut-off score for each to be considered for the Southern Italian population. Materials and Methods: A total of 144 patients were recruited in the study. The age range was 46–85 years. All subjects underwent spirometry, and completed the five questionnaires: CDQ, LFQ, COPD-PS, COPD-SQ, and CAPTURE. Receiver-operator curves (ROC) were drawn for each questionnaire. The area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), values for the optimal cut-off score and previously recommended score were calculated and compared. Results: Of the questionnaires, the CDQ, LFQ, and COPD-SQ had significant differences between COPD (n = 86) and non-COPD (n = 52) groups. The AUCs for each questionnaire with (95%CI) were: CAPTURE, 0.602 (0.431–0.773); CDQ, 0.714 (0.555–0.872); LFQ, 0.331 (0.183–0.479; COPD-PS, 0.652 (0.497–0.807); and COPD-SQ, 0.679 (0.520–0.837). Only the CDQ and COPD-SQ had significant AUC screening characteristics. The optimal cut-off values for the CDQ, LFQ, and COPD-PS were modified to 22, 10, and 4, respectively. The COPD-SQ remained at 17. Conclusion: The CDQ and COPD-SQ can discriminate between individuals with and without COPD in the Italian population. The CDQ has a moderate screening accuracy, and the COPD-PS and COPD-SQ have low accuracy, when the optimal cut-off scores are used. Of the five questionnaires assessed, the CDQ and COPD-SQ questionnaires could be used for screening for COPD in the Southern Italian population.
Open AccessAssessment of Five Questionnaires for Chronic Obstructive Pulmonary Disease in a Southern Italian Population: A Proof-of-Concept Study
Background and Objectives: Chronic obstructive pulmonary disease (COPD) is a growing burden to society, and remains underdiagnosed in Italy. This study aimed at evaluating five validated screening questionnaires to consider which one was the most accurate, and the optimal cut-off score for each to be considered for the Southern Italian population. Materials and Methods: A total of 144 patients were recruited in the study. The age range was 46–85 years. All subjects underwent spirometry, and completed the five questionnaires: CDQ, LFQ, COPD-PS, COPD-SQ, and CAPTURE. Receiver-operator curves (ROC) were drawn for each questionnaire. The area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), values for the optimal cut-off score and previously recommended score were calculated and compared. Results: Of the questionnaires, the CDQ, LFQ, and COPD-SQ had significant differences between COPD (n = 86) and non-COPD (n = 52) groups. The AUCs for each questionnaire with (95%CI) were: CAPTURE, 0.602 (0.431–0.773); CDQ, 0.714 (0.555–0.872); LFQ, 0.331 (0.183–0.479; COPD-PS, 0.652 (0.497–0.807); and COPD-SQ, 0.679 (0.520–0.837). Only the CDQ and COPD-SQ had significant AUC screening characteristics. The optimal cut-off values for the CDQ, LFQ, and COPD-PS were modified to 22, 10, and 4, respectively. The COPD-SQ remained at 17. Conclusion: The CDQ and COPD-SQ can discriminate between individuals with and without COPD in the Italian population. The CDQ has a moderate screening accuracy, and the COPD-PS and COPD-SQ have low accuracy, when the optimal cut-off scores are used. Of the five questionnaires assessed, the CDQ and COPD-SQ questionnaires could be used for screening for COPD in the Southern Italian population.
- 13 February 2023
- Vol. 94 (1) , e2023028
Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a frequent comorbidity in severe eosinophilic asthma (SEA), which may contribute to the loss of asthma control. CRSwNP and SEA share a T2-mediated mechanism and the use of some anti-asthma monoclonal antibodies has recently been extended to CRSwNP. Unlike dupilumab and omalizumab, benralizumab approval for CRSwNP is ongoing. We aimed to evaluate the efficacy of benralizumab efficacy on SEA and on CRSwNP in patients affected by both pathologies in a real life setting. 17 patients affected by both SEA and CRSwNP participated to our study. At baseline (T0) and at one year after benralizumab initiation (T1), all participants underwent spirometry, exhaled nitric oxide (FeNO), Asthma Control Test (ACT), nasal endoscopy with Nasal Polyp Score (NPS), nasal cytology and Sino-Nasal Outcome Test 22 (SNOT 22).The continuous oral corticosteroid therapy (OCS), the number of year exacerbations and the need for sinus surgery were also evaluated for each patient. At T1, a marked reduction of SNOT-22, NPS, nasal eosinophils and neutrophils count were shown compared to T0. Moreover, at T1 ACT was significantly increased and FeNO, exacerbations/year and mean OCS dosage were significantly reduced compared to T0. Our real-life study demonstrates the efficacy of benralizumab not only on SEA but also on nasal cytology and on nasal polyposis, confirming that patients affected by both SEA and CRSwNP may receive a considerable benefit from anti-IL5 receptor, treating both the comorbidities at once.
- 13 February 2023
- Vol. 94 (1) , e2023028
Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a frequent comorbidity in severe eosinophilic asthma (SEA), which may contribute to the loss of asthma control. CRSwNP and SEA share a T2-mediated mechanism and the use of some anti-asthma monoclonal antibodies has recently been extended to CRSwNP. Unlike dupilumab and omalizumab, benralizumab approval for CRSwNP is ongoing. We aimed to evaluate the efficacy of benralizumab efficacy on SEA and on CRSwNP in patients affected by both pathologies in a real life setting. 17 patients affected by both SEA and CRSwNP participated to our study. At baseline (T0) and at one year after benralizumab initiation (T1), all participants underwent spirometry, exhaled nitric oxide (FeNO), Asthma Control Test (ACT), nasal endoscopy with Nasal Polyp Score (NPS), nasal cytology and Sino-Nasal Outcome Test 22 (SNOT 22).The continuous oral corticosteroid therapy (OCS), the number of year exacerbations and the need for sinus surgery were also evaluated for each patient. At T1, a marked reduction of SNOT-22, NPS, nasal eosinophils and neutrophils count were shown compared to T0. Moreover, at T1 ACT was significantly increased and FeNO, exacerbations/year and mean OCS dosage were significantly reduced compared to T0. Our real-life study demonstrates the efficacy of benralizumab not only on SEA but also on nasal cytology and on nasal polyposis, confirming that patients affected by both SEA and CRSwNP may receive a considerable benefit from anti-IL5 receptor, treating both the comorbidities at once.
- 23 June 2022
- Published by Springer Nature in Sleep and Breathing
- Vol. 27 (2) , 611-620
Predictive tools for nocturnal respiratory failure in patients with moderate and severe OSAS
Purpose The impact of obstructive sleep apnea syndrome (OSAS) in terms of mortality, morbidity, and quality of life has been well established. Phenotyping OSAS is essential in order to make the best therapeutic choice. A particular subset of patients with OSAS shows nocturnal respiratory failure, defined by a nighttime oxygen saturation <90% in more than 30% of the total sleep time (TST90). The aim of this study was to identify possible predictive factors for nighttime respiratory failure (NRF) in patients with OSAS. Methods In this retrospective study, patients with suspected OSAS who underwent a sleep study were enrolled. Of 116 patients with moderate/severe OSAS who met the inclusion criteria, 67 also had nocturnal respiratory failure. We compared clinical, anthropometric, and laboratory data in patients with OSAS vs. OSAS and nocturnal respiratory failure. Results Patients with OSAS and nocturnal respiratory failure were more frequently female, had a higher BMI, lower daytime oxygen partial pressure (PaO2) in arterial blood, higher Apnea Hypopnea Index (AHI), and a lower number of sleep hours per night. Chronic obstructive pulmonary disease (COPD) was more diagnosed in the group of patients with nocturnal respiratory failure. A lower number of total sleep hours, lower daytime PaO2, lower AHI, increased oxygen desaturation index (ODI), and the presence of a diagnosed COPD were all found to increase the risk of having nocturnal respiratory failure. Conclusion COPD, AHI, ODI, daytime PaO2, and total sleep hours are the main predictors for NRF in patients with moderate and severe OSAS.
- 23 June 2022
- Published by Springer Nature in Sleep and Breathing
- Vol. 27 (2) , 611-620
Predictive tools for nocturnal respiratory failure in patients with moderate and severe OSAS
Purpose The impact of obstructive sleep apnea syndrome (OSAS) in terms of mortality, morbidity, and quality of life has been well established. Phenotyping OSAS is essential in order to make the best therapeutic choice. A particular subset of patients with OSAS shows nocturnal respiratory failure, defined by a nighttime oxygen saturation <90% in more than 30% of the total sleep time (TST90). The aim of this study was to identify possible predictive factors for nighttime respiratory failure (NRF) in patients with OSAS. Methods In this retrospective study, patients with suspected OSAS who underwent a sleep study were enrolled. Of 116 patients with moderate/severe OSAS who met the inclusion criteria, 67 also had nocturnal respiratory failure. We compared clinical, anthropometric, and laboratory data in patients with OSAS vs. OSAS and nocturnal respiratory failure. Results Patients with OSAS and nocturnal respiratory failure were more frequently female, had a higher BMI, lower daytime oxygen partial pressure (PaO2) in arterial blood, higher Apnea Hypopnea Index (AHI), and a lower number of sleep hours per night. Chronic obstructive pulmonary disease (COPD) was more diagnosed in the group of patients with nocturnal respiratory failure. A lower number of total sleep hours, lower daytime PaO2, lower AHI, increased oxygen desaturation index (ODI), and the presence of a diagnosed COPD were all found to increase the risk of having nocturnal respiratory failure. Conclusion COPD, AHI, ODI, daytime PaO2, and total sleep hours are the main predictors for NRF in patients with moderate and severe OSAS.
- 1 October 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 187, 106556
Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure
- 1 October 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 187, 106556
Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure
- Open Access
- 28 September 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.
- 28 September 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Open AccessImpact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.